Serum Level of Soluble -Like 2 in Renal Allograft Recipients With Acute Rejection: A Preliminary Study

Z. Zhao, C. Yang, Q. Tang, T. Zhao, Y. Jia, Z. Ma, R. Rong, M. Xu, and T. Zhu

ABSTRACT Background. Soluble fibrinogen-like protein 2 (sfgl2), which is mainly secreted by T cells, is a novel effector of regulatory T cells with immunosuppressive functions. The aim of this study was to investigate serum levels of sfgl2 among renal allograft recipients. Methods. From November 2010 to August 2011 we retrospectively divided 47 renal allograft recipients into an acute rejection (n ϭ 19) versus a stable group (n ϭ 28) according to allograft biopsy results, using the Banff 2007 classification. The acute rejection group was subdivided into grade I (n ϭ 8) versus grade II T-cell–mediated (n ϭ 6) or antibody-mediated rejection episodes (n ϭ 5). Peripheral blood samples were collected at the time of biopsy. Fourteen healthy volunteers were included as normal group controls. Serum levels of sfgl2 were analyzed by enzyme-linked immunosorbent assay. Results. Serum levels of sfgl2 were increased among renal allograft recipients suffering from biopsy-proven acute rejection episodes (61.91 Ϯ 45.68 ng/mL), versus those with stable allografts (38.59 Ϯ 19.92 ng/mL, P Ͻ .05) or healthy volunteers (29.10 Ϯ 18.08 ng/mL, P Ͻ .05). The sfgl2 level was significantly higher among patients with antibody- mediated (118.48 Ϯ 55.54 ng/mL) than T-cell–mediated acute rejection episodes (41.71 Ϯ 16.44 ng/mL, P Ͻ .01). Serum sfgl2 levels were remarkably elevated in patients with grade II (51.87 Ϯ 19.13 ng/mL) versus grade I T-cell–mediated rejection (34.10 Ϯ 9.26 ng/mL, P Ͻ .05). Conclusions. Serum sfgl2 levels were increased among renal allograft recipients with acute rejection episodes to an extent dependent upon the pathological type and severity of the response.

IDNEY TRANSPLANTATION SUCCESS is limited Soluble fgl2 (sfgl2) has been recently identified as an- K by acute rejection episodes miphros toxicity, malig- other form of fgl2. It is mainly secreted by CD4ϩ and CD8ϩ nancy, and cardiovascular complications.1 Despite the im- T cells, especially regulatory T cells (Tregs).8 sfgl2 serves as provements in immunosuppressants, acute rejection, an an effector of Tregs, demonstrating immunoregulatory unsolved problem, contributes to morbidity and mortality functions.9 sfgl2 inhibits dendritic cell maturation and in- after kidney transplantation. T cells and antibodies are duces B cell apoptosis in vitro, while down-regulation of major factors involved in acute rejection, employing mech- sfgl2 improves T-cell proliferation, promotes Th1 cell po- anisms that remain not fully understood. Fibrinogen-like protein 2 (fgl2/fibroleukin), a member of the fibrinogen-related protein superfamily, has a membrane- From the Department of Urology, Zhongshan Hospital, Fudan protein form, fgl2 prothrombinase, that is mostly expressed on University (Z.Z., C.Y., Q.T., Y.J., R.R., T.Z.); Shanghai Key reticuloendothelial cells, playing procoagulant activity in im- Laboratory of Organ Transplantation (C.Y., T.Z., M.X., T.Z.); and mune-associated coagulation.2 It is up-regulated in several Clinical Laboratory, Zhongshan Hospital, Fudan University (Z.M.), Shanghai, PR China. inflammatory disorders such as viral hepatitis,3 graft rejec- 4 5 Grants provided by the National Nature Science Foundation of tion, and autoimmune glomerulonephritis. In organ trans- China (No. 81070595); Science and Technology Commission of 6,7 4 plant settings in both animals and humans , high expres- Shanghai Municipality (No. 10DZ2212000). sion of fgl2 prothrombinase is seen in grafts experiencing Address reprint requests to Tongyu Zhu, 180 Fenglin Road, acute rejection responses. Shanghai, 200032, China. E-mail: [email protected]

0041-1345/12/$–see front matter Crown Copyright © 2012 Published by Elseiver Inc. All rights reserved. http://dx.doi.org/10.1016/j.transproceed.2012.05.082 360 Park Avenue South, New York, NY 10010-1710

2982 Transplantation Proceedings, 44, 2982–2985 (2012) SERUM LEVEL OF SOLUBLE FIBRINOGEN-LIKE PROTEIN 2 2983 larization, and inhibits Treg activity.10 The changes in sfgl2 tistics 19.0 (International Business Machines Corp, New York, NY, expression during acute rejection episodes after kidney USA) was used for data analysis. Student t test was employed to transplantation, however, remain unclear. This study sought compare continuous variables between groups, while Pearson ␹2 Ͻ to investigate serum levels of sfgl2 among renal transplant -test for categorical data. A two-tailed P .05 was considered recipients with biopsy-proven T-cell– or antibody-mediated statistically significant. acute rejection episodes, compared with those among re- cipients with stable allografts or healthy volunteers. RESULTS Baseline Characteristics of Groups MATERIALS AND METHODS Baseline characteristics of each group are shown in Table 1. Demographics There was no significant difference among the groups in the From November 2010 to August 2011 we enrolled 47 renal values of mean age, sex, induction therapy, cold ischemia transplant recipients who underwent allograft biopsies in this study. time, immunosuppressant, or posttransplantation time. 19 recipients showed acute rejection episodes based upon the Banff 2007 classification system,11 including 14 with T-cell– and five with Serum Levels of sfgl2 antibody-mediated rejection. No rejection was discovered among the other 28 recipients, who maintained stable renal function for at Serum levels of sfgl2 were significantly higher among least 6 months. All patients administered cyclosporine or tacroli- patients with acute rejection episodes (61.91 Ϯ 45.68 ng/ mus plus mycophenolate mofetil and prednisone. Patients were mL, n ϭ 19) versus those with stable allografts (38.59 Ϯ excluded if they had undergone a multiorgan transplantation, were 19.92 ng/mL, n ϭ 28, P Ͻ .05) or healthy volunteers (29.10 Ϯ experiencing a generalized infection at the time of transplantation, 18.08 ng/mL, n ϭ 14, P Ͻ .05) (Fig 1). There was no had a history of malignancy, or were positive for HIV, antibody, or surface antigen. Also, 14 healthy significant difference between the stable and the normal volunteers were included as a normal group. Approval for this groups. Serum sfgl2 levels were significantly higher among study was obtained from our ethics committee. subjects experiencing antibody-mediated (118.48 Ϯ 55.54 ng/mL, n ϭ 5) versus T-cell–mediated rejection episodes Serum Levels of sfgl2 (41.71 Ϯ 16.44 ng/mL, n ϭ 14, P Ͻ .01) according to the Peripheral blood samples were obtained from the patients at the Banff 2007 criteria. Among the patients with T-cell–medi- time of biopsy and from healthy volunteers. Serum levels of sfgl2 ated acute rejections, serum sfgl2 was remarkably higher in were measured using enzyme-linked immunosorbent assay the grade II (51.87 Ϯ 19.13 ng/mL, n ϭ 6) versus the grade (ELISA) kits (Biolegend, San Diego, Calif, USA) according to the I subset (34.10 Ϯ 9.26 ng/mL, n ϭ 8, P Ͻ .05). manufacturer’s instructions. Briefly, serum samples (30 ␮L) were added to each well of a plate precoated with anti-human fgl2 DISCUSSION antibodies. Following 2-hour incubation at room temperature and four washes with buffer, 100 ␮L of human fgl2 detection antibody Acute rejection remains a formidable problem in kidney was added to each well for a 1-hour incubation at room tempera- transplantation, impairing allograft function and recipient ture. The plate was washed again and treated with secondary survival. It is of great importance to understand the mech- horseradish peroxidase-conjugated antibodies. After another five anisms of acute rejection seeking critical molecules in this washes, 100 ␮L of substrate solution were then added for a process. sfgl2, a novel effector secreted by Tregs, exerts 20-minute incubation in the dark. After the reaction was stopped, absorbance was measured at 450 nm using an ELISA plate reader. immunoregulatory functions. Current research on sfgl2 is The concentration was determined using a standard curve accord- mostly limited to in vitro experiments and animal models, ing to the kits instructions. rather than transplantations. In this study, we first demon- strated that serum sfgl2 levels were remarkably elevated Statistics among renal allograft recipients suffering acute rejection Baseline characteristics and data were presented as mean values Ϯ episodes, compared with these displaying stable allografts standard deviations or frequencies (percentages). IBM SPSS Sta- or healthy volunteers. Furthermore, serum sfgl2 levels were

Table 1. Baseline Characteristics

All Groups Normal Group Stable Group Acute Rejection Group P Value

Number 61 14 28 19 — Age (y)a 46.0 Ϯ 16.9 61.6 Ϯ 12.4 46.4 Ϯ 15.2 43.9 Ϯ 15.5 Ͼ.05 Sex (M/F)b 47 (77%)/14 (23%) 8 (57%)/6 (43%) 23 (82%)/5 (18%) 16 (84%)/3 (16%) Ͼ.05 Induction therapy (CD25 mAb/ATG)b — — 26 (93%)/2 (7%) 18 (95%)/1 (5%) Ͼ.05 Cold ischemia time (h)a — — 7.4 Ϯ 2.1 7.8 Ϯ 2.3 Ͼ.05 Immunosuppressant (MMF ϩ CsA ϩ — — 15 (54%)/13 (46%) 10 (53%)/9 (47%) Ͼ.05 Pre/MMF ϩ FK506 ϩ Pre)b Posttransplantation time (y)a — — 3.7 Ϯ 3.1 3.5 Ϯ 3.2 Ͼ.05

mAb, monoclonal antibody; ATG, antithymocyte globulin; MMF, mycophenolate mofetil; CsA, cyclosporine; FK506, tacrolimus; Pre, prednisone. aMean Ϯ standard deviations. bFrequence (percentage). 2984 ZHAO, YANG, TANG ET AL significantly higher in antibody-mediated versus T-cell– mediated rejection episodes as well as among grade II versus grade I rejections. Tregs are believed to play an important role in the induction and maintenance of .12 In the same way, Tregs can also be recruited into the graft during acute rejection in order to restrain the inflammation.13 Recent findings in experimental transplant models have shown Tregs to increase during acute rejection to diminish inflammation and associated lesions, thereby ameliorating acute rejection.14,15 Moreover, enhanced numbers and functions of Tregs have been shown in peripheral blood during aggressive acute rejection responses.16 These obser- vations are consistent with our findings of increased sfgl2 expression in renal allograft recipients experiencing acute Fig 2. The soluble fibrinogen-like protein 2 (sfgl2) level was rejection episodes and the higher levels among grade II significantly higher in patients with antibody-mediated acute versus grade I T-cell–mediated acute rejection episodes rejection than those with T-cell–mediated acute rejection (P Ͻ (Figs 2 and 3). Furthermore, serum sfgl2 has been shown to .01). **P Ͻ .01. be associated with circulating Tregs in some diseases. Elevated peripheral sfgl2 levels seem to correlate with Recently a French study examined the immunosuppres- increased percentages of Tregs in a fulminant viral hepatitis ϩ low model in mice.17 In clinical settings, serum and tissue fgl2 sive role of fgl2 in CD8 CD45RC regulatory T-cell– mediated long-term rat of cardiac transplant survival using contents have been demonstrated to be a surrogates for 19 Treg activity in patients with chronic viral hepatitis C.18 Our a strategy of CD40-CD40L blockade. They demonstrated study suggested an association of sfgl2 with acute rejection greater expression of fgl2 in the graft and among splenie severity in kidney transplantation. Regarding the recent Tregs at both the mRNA and the protein levels suggesting finding that Tregs were associated with more aggressive fgl2 involvement in Treg immunosuppressive function by in acute rejection disease, we believe that measurements of vitro and in vivo methods. We showed lower, serum sfgl2 serum sfgl2 may provide a potential marker for circulating levels in the stable group or healthy volunteers versus the Treg activity to evaluate rejection severity. acute rejection cohort. This result may have been due to the This study also demonstrated that serum sfgl2 was signif- different locations of measurement of sfgl2. In tolerant icantly higher among patients with antibody-mediated ver- circumstances, Tregs not only migrate from the spleen but also are generated in the graft,13 as well as accumulate in sus T-cell–mediated acute rejection episodes, which sug- 20 gests that Tregs might not be the only source of sfgl2. The renal allografts as driven by certain chemokines. There- other cells involved in the secretion of sfgl2 such as B-cell fore, we believe that the lower serum sfgl2 level in the stable subsets are increased to a greater extent in antibody- group was due to an attraction of Tregs to the graft with mediated than T-cell–mediated rejection. sfgl2 secretion, reducing the content in the peripheral

Fig 1. Serum level of soluble fibrinogen-like protein 2 (sfgl2) Fig 3. Serum soluble fibrogen-like protein 2 (sfgl2) level re- increased in renal allograft recipients suffered from biopsy- markably elevated in patients with grade II T-cell–mediated proven acute rejection, compared to those with stable allografts rejection than those with grade I (P Ͻ .05). *P Ͻ .05. TCMR, (P Ͻ .05) and healthy volunteers (P Ͻ .05). *P Ͻ .05. T-cell–mediated rejection. SERUM LEVEL OF SOLUBLE FIBRINOGEN-LIKE PROTEIN 2 2985 blood. Furthermore, in the French study, researchers in- and acute vascular rejection in cardiac xenografts. Circulation jected recipients with fibrinogen-like protein 2 recombinant 112:248, 2005 virus before transplantation, which also contributed to sfgl2 7. Ghanekar A, Mendicino M, Liu H, et al: Endothelial induc- tion of fgl2 contributes to during acute vascular xeno- overexpression. graft rejection. J Immunol 172:5693, 2004 In a liver transplant tolerance animal model,21 increased 8. Marazzi S, Blum S, Hartmann R, et al: Characterization of expressions of the fgl2 as well as the set of inflamma- human fibroleukin, a fibrinogen-like protein secreted by T lympho- tory were observed in the early stage posttransplan- cytes. J Immunol 161:138, 1998 9. Denning TL, Granger SW, Mucida D, et al: Mouse tation. Once the allograft had been fully accepted, the TCRalphabetaϩCD8alphaalpha intraepithelial lymphocytes ex- expression of the inflammatory genes returned to baseline press genes that down-regulate their antigen reactivity and sup- while fgl2 expression still remained increased. This phe- press immune responses. J Immunol 178:4230, 2007 nomenon suggested that continuous evaluation of sfgl2 10. Chan CW, Kay LS, Khadaroo RG, et al: Soluble fibrinogen- expression during the acute rejection process will provide like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing proliferation and inhibiting maturation of bone more information to better understand its role in transplan- marrow-derived dendritic cells. J Immunol 170:4036, 2003 tation. 11. Solez K, Colvin RB, Racusen LC, et al: Banff 07 classifica- In conclusion, this study documented increased serum sfgl2 tion of renal allograft pathology: updates and future directions. levels among renal allograft recipients with acute rejection Am J Transplant 8:753, 2008 12. Wood KJ: Regulatory T cells in transplantation. Transplant episodes. Serum sfgl2 was significantly higher in antibody- Proc 43:2135, 2011 mediated than T-cell–mediated rejection episodes and in 13. Wei S, Kryczek I, Zou W: Regulatory T-cell compartmen- grade II versus grade I processes. Elevated sfgl2 may reflect talization and trafficking. Blood 108:426, 2006 activation of immunoregulatory responses during acute rejec- 14. Aquino-Dias EC, Joelsons G, da Silva DM, et al: Non- tion, rendering it to be a potential index for immune evalua- invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int 73:877, 2008 tion after kidney transplantation. 15. Taflin C, Nochy D, Hill G, et al: Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft REFERENCES function. Transplantation 89:194, 2010 16. Dummer CD, Carpio VN, Goncalves LF, et al: FOXP3ϩ 1. Pascual M, Theruvath T, Kawai T, et al: Strategies to improve regulatory T cells: from suppression of rejection to induction of long-term outcomes after renal transplantation. N Engl J Med renal allograft tolerance. Transpl Immunol 26:1, 2012 346:580, 2002 17. Shalev I, Wong KM, Foerster K, et al: The novel 2. Yuwaraj S, Ding J, Liu M, et al: Genomic characterization, CD4ϩCD25ϩ effector molecule fibrinogen-like localization, and functional expression of FGL2, the human gene protein 2 contributes to the outcome of murine fulminant viral encoding fibroleukin: a novel human procoagulant Genomics 71: hepatitis. Hepatology 49:387, 2009 330, 2001 18. Foerster K, Helmy A, Zhu Y, et al: The novel immunoregu- 3. Zhu CL, Yan WM, Zhu F, et al: Fibrinogen-like protein 2 latory molecule FGL2: a potential biomarker for severity of chronic fibroleukin expression and its correlation with disease progression hepatitis C virus infection. J Hepatol 53:608, 2010 in murine hepatitis virus type 3-induced fulminant hepatitis and in 19. Séverine Bézie SM, Laurent T, Li XL, et al: Immunosup- patients with severe viral hepatitis B. World J Gastroenterol pressive role of fibrinogen-like protein 2 (FGL2) in 11:6936, 2005 CD8ϩregulatory T cells-mediated long-term graft survival. J 4. Ning Q, Sun Y, Han M, et al: Role of fibrinogen-like protein Transl Med 9(suppl 2):O5, 2011 2 prothrombinase/fibroleukin in experimental and human allograft 20. Zhang N, Schroppel B, Lal G, et al: Regulatory T cells rejection. J Immunol 174:7403, 2005 sequentially migrate from inflamed tissues to draining lymph nodes 5. Shalev I, Liu H, Koscik C, et al: Targeted deletion of fgl2 to suppress the alloimmune response. Immunity 30:458, 2009 leads to impaired regulatory T cell activity and development of 21. Xie L, Ichimaru M, Morita M, et al: Identification of a novel autoimmune glomerulonephritis. J Immunol 180:249, 2008 biomarker gene set with sensitivity and specificity to distinguish 6. Mendicino M, Liu M, Ghanekar A, et al: Targeted deletion of between allograft rejection and tolerance. Liver Transpl 18:444, Fgl-2/fibroleukin in the donor modulates immunologic response 2012